Thursday, 5 November 2026European Markets
ExploreSearch
ViaNews EU
stockMarket

Bank Of Ireland Stock Plummets 16% In Recent Sessions - What's Behind The Decline?

Loading stream...

(VIANEWS) - Dublin, Ireland - Shares of BANK OF IR NC PREF (ISEQ All Share: DD7E.IR) have experienced an alarming 16.01% drop over the last five trading sessions, losing 16.01% in value from opening at EUR24.05.20 at 15:27 EST to closing at EUR20.20 by 15:27 EST Tuesday 15th August; continuing its downward spiral and suffering five straight sessions of losses. The Irish Stock Exchange All Share Index, which tracks all companies listed on its main market, has also seen its value fall by 0.43% to EUR8,837.27 as of 15:27 EST today - following two consecutive days of losses for this index. Investors should closely track the performance of these stocks and the market as recent declines could signal a shift in sentiment.

More news about BANK OF IR NC PREF (DD7E.IR).

Categories

stockMarket

Tags

DD7E.IRStock PricePrice DownMarket Session NowStock Price DownStock Market NowMarket SessionStock MarketStockBANK OF IR NC PREF
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Oncology Data Season and Biotech Capital Allocation: ESMO Readouts, Ivonescimab PDUFA, and Diverging Corporate Moves
Late-2026 biotech is driven by a dense catalyst calendar. ESMO 2026 delivers data from ivonescimab, Enhertu, R-DXd and bemarituzumab, and the FDA has set a 14 Nov PDUFA date for the ivonescimab BLA. Capital allocation is diverging. Krystal Biotech authorized a $400M buyback while lowering FY2026 spend guidance and pushing milestones into 2027. Spago is moving to delist from Nasdaq First North. The facts are clinical and corporate events, not AI or fintech, so the finance angle is limited to capital markets (buybacks, guidance, delistings, regulatory timelines).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,549 source documents archived
Query this data → isubstrate.com